NHS
Calderdale
Clinical Commissioning Group

Commissioning Policy

Treatment (brand name, manufacturer if applicable)	**Anagrelide (Xagrid®, Shire Pharmaceuticals)**
For the treatment of	Essential thrombocythaemia in patients at risk of thrombo-haemorrhagic events who have not responded adequately to other drugs or who cannot tolerate other drugs
Background	No NICE Guidance is available or in production for this medicine. SMC Guidance was issued in October 2005 see summary of evidence below. Excluded from PbR tariff Xagrid is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at risk patient An at risk essential thrombocythaemia patient is defined by one or more of the following features: • > 60 years of age or • a platelet count > 1000 x 109/l or • a history of thrombo-haemorrhagic events
Commissioning position	NHS Calderdale CCG ***will routinely commission*** the use of anagrelide in line with its licensed indication. Anagrelide will be used second line to hydroxycarbamide in patients who are intolerant to this treatment or in whom there is an inadequate response.
Effective from	January 2012
Summary of evidence/rationale	SMC Advice October 2005 Following a resubmission: Anagrelide (Xagrid) is accepted for use within NHS Scotland for the reduction of elevated platelet counts in at-risk patients with essential thrombocythaemia who are intolerant of their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. Anagrelide reduces platelet counts in patients with essential thrombocythaemia who were intolerant of another cytoreductive therapy or whose platelet count could not be controlled by it.
Date	December 2011

NHS
Calderdale
Clinical Commissioning Group

Policy to be reviewed by	December 2013
Contact for this policy	Helen Foster – Medicines Management Pharmacist Helen.Foster@calderdaleccg.nhs.uk